Vps16 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Vps16 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
VPS16 (vacuolar protein sorting 16 homolog) encodes a core tethering factor in the class C VPS machinery that controls late endosome and lysosome fusion. In mammalian cells, VPS16 functions as a scaffold that helps assemble and stabilize membrane-tethering complexes required for cargo progression toward degradation. This places VPS16 at a key control point for neuronal proteostasis, because [neurons](/entities/neurons) depend on efficient endolysosomal flux to clear damaged proteins and organelles.[@steel2020][@van2024]
From a neurodegeneration perspective, VPS16 is relevant because endolysosomal stress is a convergent mechanism across [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and related disorders. Impaired late endosome-lysosome fusion can amplify aggregate accumulation, inflammatory signaling, and synaptic vulnerability.[@kaur2018][@mony2020]
<div class="infobox infobox-gene">
| Property | Value |
|---|---|
| Gene Symbol | VPS16 |
| Full Name | Vacuolar Protein Sorting 16 Homolog |
| Chromosomal Location | 20q13.33 |
| NCBI Gene ID | 64601 |
| OMIM | 614464 |
| Ensembl ID | ENSG00000112357 |
| UniProt ID | Q9H269 |
| Core Complex Context | HOPS/CORVET-class tethering machinery |
</div>
Biochemical and structural work shows that VPS16 provides a recruitment platform for SM-family proteins (including VPS33A) within the HOPS architecture, enabling productive docking and fusion of late endosomal and lysosomal membranes.[@graham2013][@van2015] In practical terms, VPS16 helps convert vesicle encounters into fusion-competent events.
VPS16-dependent HOPS activity is needed for completion of macroautophagy, especially the final fusion step that delivers autophagic cargo to acidic lysosomes.[@van2024][@abudu2015] When this step fails, autophagic vacuoles and undegraded substrates accumulate, increasing neuronal stress.
Neurons are particularly sensitive to partial loss of VPS16 pathway capacity because they are long-lived, highly polarized, and generate high membrane-trafficking load. Persistent traffic delay in distal compartments can alter synaptic maintenance and axonal health.[@kaur2018][@ando2022]
Human genetics has established VPS16 as a disease gene: loss-of-function variants can cause early-onset dystonia with lysosomal abnormalities, and biallelic variants have been linked to a mucopolysaccharidosis-like syndrome with reduced HOPS/CORVET complex levels.[@steel2020][@zahra2021] These disorders provide strong in vivo evidence that VPS16 dosage is biologically critical in the nervous system.
Although VPS16 is not a major common-risk locus in [Parkinson's disease](/diseases/parkinsons-disease) or [Alzheimer's disease](/diseases/alzheimers-disease), the pathway it controls overlaps with disease mechanisms involving aggregate-prone proteins such as [SNCA](/genes/snca), [APP](/genes/app), and [MAPT](/genes/mapt). Endolysosomal bottlenecks can increase toxic protein residence time and weaken organelle turnover.[@kaur2018][@mony2020]
VPS16 function is tightly coupled to other vesicle-tethering genes, including [VPS33A](/genes/vps33a) and [VPS41](/genes/vps41). Defects across this module are expected to produce shared phenotypes: impaired cargo maturation, stress-response activation, and selective neuronal vulnerability.[@van2024][@graham2013]
Common laboratory readouts for VPS16-pathway dysfunction include:
In translational studies, these cellular signatures can complement clinical phenotyping to stratify patients with suspected endolysosomal disorders.[@steel2020][@zahra2021]
For VPS16-linked dysfunction, plausible intervention strategies include:
These are mechanism-led approaches relevant across multiple neurodegenerative contexts, not just rare VPS16 syndromes.[@kaur2018][@xiao2021]
For confirmed pathogenic VPS16 variants, future options may include variant-specific molecular therapies or gene-dosage correction, but clinical evidence is still limited and remains investigational.[@zahra2021]
The study of Vps16 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The following diagram shows the key molecular relationships involving VPS16 Gene discovered through SciDEX knowledge graph analysis:
Sources: [GTEx Portal v10](https://gtexportal.org/home/gene/vps16) | [Allen Brain Atlas](https://www.brain-map.org/)
| Rank | Tissue | Median TPM |
|------|--------|------------|
| 1 | Thyroid | 58.23 |
| 2 | Brain Cerebellum | 57.77 |
| 3 | Uterus | 55.85 |
| 4 | Brain Cerebellar Hemisphere | 54.57 |
| 5 | Cervix Endocervix | 52.02 |
| 6 | Cervix Ectocervix | 51.79 |
| 7 | Fallopian Tube | 51.05 |
| 8 | Spleen | 48.43 |
| 9 | Ovary | 46.07 |
| 10 | Nerve Tibial | 43.33 |
| 11 | Prostate | 43.15 |
| 12 | Lung | 42.65 |
| 13 | Vagina | 39.63 |
| 14 | Small Intestine Terminal Ileum | 37.34 |
| 15 | Adipose Subcutaneous | 36.89 |
Brain-Region Expression:
| Region | Median TPM |
|--------|------------|
| Brain Cerebellum | 57.77 |
| Brain Cerebellar Hemisphere | 54.57 |